MedTrace Logo

Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project

NCT02948088 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 183

Last updated 2023-10-31

Study results available
· View outcomes & findings →

Summary

TGCT is a rare disease that is difficult to manage, surgical resection is the primary treatment currently available. To date no disease registry exists and there is little data available detailing the management of patients with diffuse TGCT (d-TGCT), the burden of d-TGCT for patients (including pain, joint stiffness, swelling, reduced mobility and quality of life) or the economic impact of d-TGCT.

This study aims to collect data by an observational disease registry involving no intervention to the patient or changes to investigators treatment decisions.

Conditions

  • Giant Cell Tumors

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Leader · Daiichi Sankyo

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-18
Primary Completion
2021-03-11
Completion
2021-03-11

Countries

  • United States
  • Austria
  • France
  • Germany
  • Italy
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02948088 on ClinicalTrials.gov